The Japanese journal of thoracic diseases 

About: The Japanese journal of thoracic diseases is an academic journal. The journal publishes majorly in the area(s): Lung & Bronchoalveolar lavage. It has an ISSN identifier of 0301-1542. Over the lifetime, 3960 publications have been published receiving 7239 citations.

[Diagnosis, incidence, clinicopathology and surgical treatment of acquired tracheobronchomalacia].

Abstract: We report our recent findings on the diagnosis, incidence, appearance of the trachea at autopsy, and surgical treatment of acquired trachobronchomalacia. In the diagnosis of this disease, continuous dynamic CT scanning (1 slice/0.6 second) from inspiration to deep expiration was better than X-ray cine recording. It is difficult to observe the most collapsed airway on coughing using bronchofiberscopic recording, because its duration time was estimated to be 1/10 second by X-ray cine recording, whereas the findings at one instant were easily recorded by video-bronchoscopy on coughing. The degree of severity of this disease was classified into three groups. 1st degree 0-50% narrowing of airway caliber, 2nd degree 50-75%; and 3rd degree 75-100%. Severity of 2nd or 3rd degree was present in 542 (12.7%) of 4283 patients suffering from chest disease who underwent bronchoscopy. Seventy-two percent of patients were aged 50 to 80 years. Third degree tracheomalacia was found in 131 patients with an incidence of 3.1%, which increased from 2.2% at 50 years to 6.2% at 80 years. The autopsy findings of the trachea consisted of fragmentation of the tracheal cartilage and extension of the membranous portion. The pathogenesis may be varied with different types of collapse of the airway, including the saber sheath type and the crescent type. Surgical treatment consists of prevention of the airway collapse by wrapping the airway with Marlex mesh and bonding Lyodura (lyophilized dura mata) with fibrin glue, which is more reliable than the span plasty proposed by Nissen.

Long-Term Therapeutic Effects of Erythromycin and Newquinolone Antibacterial Agents on Diffuse Panbronchiolitis

Abstract: The present study reviewed and summarized the long-term therapeutic effects of erythromycin or newquinolone antibacterial agents on diffuse panbronchiolitis. Various parameters before and after the treatment were analyzed in 101 patients selected from 227 diffuse panbronchiolitis patients gathered from 26 institutes in Japan. Patients had been treated with either erythromycin or newquinolone antibacterial agent for more than 3 months. Patients treated with erythromycin showed significant improvement of dyspnea on exertion, findings of chest X-ray, data on blood gas analysis, rate of ESR, titer of cold coagulation and amount of sputum, compared with patients treated with the newquinolone antibacterial agent. Among the patients treated with erythromycin, those patients with the initial high cold coagulation titer showed better improvement following treatment. However, there was no significant difference in improvement, depending upon either the duration between the time of onset of the disease, the initiation of treatment, and the initial severity of the disease.

Plasma DNA level as a tumor marker in primary lung cancer

Abstract: The plasma level of human DNA was determined by the dot-hybridization method using human Alu-family DNA as a probe in 45 patients with primary lung cancer, 54 patients with benign pulmonary diseases, and 59 healthy controls. The mean plasma DNA level was significantly higher in the patients with lung cancer than that in the patients with benign pulmonary diseases or in healthy controls. The mean plasma DNA level in the patients with benign pulmonary diseases was also significantly higher than that in healthy controls. There was no significant difference in mean plasma DNA level in each histologic type of lung cancer. The plasma DNA level was elevated above the cut-off level of 80 ng/ml in 71% of the patients with lung cancer, 37% of the patients with benign pulmonary diseases and none of the healthy controls. The serum CEA was positive in 38% of the patients with lung cancer and thus when plasma DNA and serum CEA were used in combination, 78% of the cases with lung cancer could be detected by these two markers. In the patients with lung cancer who responded to treatment, the plasma DNA levels were significantly decreased after treatment, while its levels were elevated in the patients whose treatment was unsuccessful. These findings indicate that plasma DNA may be a useful marker in patients with lung cancer.